Literature DB >> 22959981

Seroprevalence of seven high-risk HPV types in The Netherlands.

Mirte Scherpenisse1, Madelief Mollers, Rutger M Schepp, Hein J Boot, Hester E de Melker, Chris J L M Meijer, Guy A M Berbers, Fiona R M van der Klis.   

Abstract

BACKGROUND: To obtain insight into the age-specific seroprevalence for seven high-risk human papillomavirus (hr-HPV) serotypes (HPV16, 18, 31, 33, 45, 52, and 58) among the general population in the pre-vaccination era in The Netherlands.
METHODS: From a cross-sectional population-based study (ISRCTN 20164309) performed in 2006/2007 6384 sera of men, women and children were tested for seven hr-HPV specific antibodies using a fluorescent bead-based multiplex immunoassay with virus-like particles of the seven HPV serotypes.
RESULTS: An increase in seroprevalence was observed in adolescents, especially for the most prevalent HPV type 16 (up to 11.3%). The increase was most pronounced in women, but was less clear for the other six HPV serotypes. Relatively stable seroprevalences were found in the middle aged cohorts and a slight decrease in the elderly. For the age cohorts >14 years, the seroprevalence among women (25.2%) was higher compared with men (20.3%) (p=0.0002). We found that 10.1% of the population was seropositive for multiple HPV serotypes.
CONCLUSIONS: The HPV vaccination program is targeted at preadolescents as is justified by the results in this study in which a step-up in HPV seroprevalence is observed at ages of sexual debut. Although direct interpretation of seroprevalence data are hampered by cross-reactivity and seroconversion rate, these data are useful as baseline to evaluate long-term population effects of the HPV16/18 vaccination program.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22959981     DOI: 10.1016/j.vaccine.2012.08.068

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  20 in total

1.  Detection of systemic and mucosal HPV-specific IgG and IgA antibodies in adolescent girls one and two years after HPV vaccination.

Authors:  Mirte Scherpenisse; Madelief Mollers; Rutger M Schepp; Chris J L M Meijer; Hester E de Melker; Guy A M Berbers; Fiona R M van der Klis
Journal:  Hum Vaccin Immunother       Date:  2012-11-13       Impact factor: 3.452

2.  Determinants of High-Risk Human Papillomavirus Seroprevalence and DNA Prevalence in Mid-Adult Women.

Authors:  Patricia Sadate-Ngatchou; Joseph J Carter; Stephen E Hawes; Qinghua Feng; Taylor Lasof; Joshua E Stern; Tsung-Chieh Jane Fu; Denise A Galloway; Laura A Koutsky; Rachel L Winer
Journal:  Sex Transm Dis       Date:  2016-03       Impact factor: 2.830

3.  Comparison of different assays to assess human papillomavirus (HPV) type 16- and 18-specific antibodies after HPV infection and vaccination.

Authors:  Mirte Scherpenisse; Rutger M Schepp; Madelief Mollers; Sofie H Mooij; Chris J L M Meijer; Guy A M Berbers; Fiona R M van der Klis
Journal:  Clin Vaccine Immunol       Date:  2013-06-05

4.  DNA detection and seroprevalence of human papillomavirus in a cohort of adolescent women.

Authors:  Aaron C Ermel; Marcia L Shew; Bree A Weaver; Brahim Qadadri; Cheryl Denski; Wanzhu Tu; Yan Tong; J D Fortenberry; Darron R Brown
Journal:  Sex Transm Infect       Date:  2013-09-12       Impact factor: 3.519

5.  Characteristics of HPV-specific antibody responses induced by infection and vaccination: cross-reactivity, neutralizing activity, avidity and IgG subclasses.

Authors:  Mirte Scherpenisse; Rutger M Schepp; Madelief Mollers; Chris J L M Meijer; Guy A M Berbers; Fiona R M van der Klis
Journal:  PLoS One       Date:  2013-09-18       Impact factor: 3.240

6.  Anal, penile, and oral high-risk HPV infections and HPV seropositivity in HIV-positive and HIV-negative men who have sex with men.

Authors:  Vera M van Rijn; Sofie H Mooij; Madelief Mollers; Peter J F Snijders; Arjen G C L Speksnijder; Audrey J King; Henry J C de Vries; Arne van Eeden; Fiona R M van der Klis; Hester E de Melker; Marianne A B van der Sande; Maarten F Schim van der Loeff
Journal:  PLoS One       Date:  2014-03-20       Impact factor: 3.240

7.  Changes in antibody seroprevalence of seven high-risk HPV types between nationwide surveillance studies from 1995-96 and 2006-07 in The Netherlands.

Authors:  Mirte Scherpenisse; Madelief Mollers; Rutger M Schepp; Hein J Boot; Chris J L M Meijer; Guy A M Berbers; Fiona R M van der Klis; Hester E de Melker
Journal:  PLoS One       Date:  2012-11-12       Impact factor: 3.240

8.  Patterns of human papillomavirus DNA and antibody positivity in young males and females, suggesting a site-specific natural course of infection.

Authors:  Henrike J Vriend; Johannes A Bogaards; Fiona R M van der Klis; Mirte Scherpenisse; Hein J Boot; Audrey J King; Marianne A B van der Sande
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

9.  Cross-sectional study of HPV-16 infection in a population-based subsample of Hispanic adults.

Authors:  A P Ortiz; E R Unger; C Muñoz; G Panicker; G Tortolero-Luna; M Soto-Salgado; Y Otero; E Suárez; C M Pérez
Journal:  BMJ Open       Date:  2014-02-04       Impact factor: 2.692

10.  Serological prevalence and persistence of high-risk human papillomavirus infection among women in Santiago, Chile.

Authors:  Felipe A Castro; Angelica Dominguez; Klaus Puschel; Vanessa Van De Wyngard; Peter J F Snijders; Silvia Franceschi; Michael Pawlita; Catterina Ferreccio
Journal:  BMC Infect Dis       Date:  2014-07-03       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.